Affected market: Pharmaceuticals
No. ME/1100/04
On the basis of the information available to it, the Office of Fair Trading has decided that the proposed acquisition of Celltech Group plc by UCB SA does not qualify for investigation under the mergers provisions of the Enterprise Act 2002 (the Act), because neither the UK turnover test nor the share of supply test in section 23 of the Act is met. A relevant merger situation has, therefore, not been created.
This feature requires Javascript and Cookies to be enabled on your browser
Register for email alerts or amend your existing account details here.